Jul. 4 at 7:13 AM
$OSTX My next prediction is that big pharma is not so interested in osteosarcoma drug per se, but the gene edited listeria platform as a delivery method for a wide spectrum of immunotherapies. That direct offering could be a bridge funding before partnership with a big pharma. My list of potential suitors is:
1. Merck
2. BMS
3. Pfizer
4. Roche/Genentech
5. GSK
I think there’s a great chance we will see a partnership announcement before the 3 year data, because that concerns only osteosarcoma, not the platform itself.
Now is the perfect time to gobble up as many shares as you can.
